🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Breast Cancer Patients

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer NCT05534438Phase 28 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Stereotactic body radiotherapy Access to Genetic Testing in Underserved Patients With Cancer NCT06422455NA2 sites📍 Los Angeles📍 Rochester University of Southern California · Tests: Best Practice, Educational Intervention, Electronic Health Record Review, Genetic Counseling, Interview PREgnancy and FERtility Registry NCT02895165n/a23 sites📍 Asti📍 Brindisi📍 Monserrato IRCCS Azienda Ospedaliera Universitaria San Martino - IST I… A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs) NCT07743190Phase 22 sites📍 Syracuse📍 Charleston Medical University of South Carolina · Tests: Carboplatin, Paclitaxcel, Pembrolizumab CTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial NCT05360290NA1 site📍 Shanghai RenJi Hospital · Tests: GILUPI CellCollector® A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521Phase 1, Phase 26 sites📍 Los Angeles📍 Grand Rapids📍 Columbus Tanabe Pharma America, Inc. · Tests: MT-4561 A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse NCT06643585Phase 31 site📍 Ulm Prof. Wolfgang Janni · Tests: Trastuzumab-Deruxtecan, Physicians Choice (PhC). Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168n/a1 site📍 Sioux Falls Sanford Health PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC NCT06245889Phase 22 sites📍 Baltimore📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: Paclitaxel, Carboplatin, Pembrolizumab, Doxorubicin, Cyclophosphamide Sensitivity of Organoids to Predict Treatment Outcome in Breast Cancer Metastases NCT06468124n/a2 sites📍 London📍 London King's College London Compare Analgesia Between MTP Block And ESPB in MRM NCT06888258NA1 site📍 Cairo National Cancer Institute, Egypt · Tests: Ultrasound guided Erector Spinae Plane block, Ultrasound guided Mid-point to Pleura block Viscum Album for TNBC on Adjuvant Pembrolizumab NCT06920810Phase 41 site📍 Goyang-si Ilsan Cha hospital · Tests: viscum album Endoscopic Nipple-Sparing Mastectomy Through a Single Axillary Incision in Breast Cancer NCT07507890NA1 site📍 Candiolo Fondazione del Piemonte per l'Oncologia · Tests: Endoscopic Nipple-Sparing Mastectomy (E-NSM) Manual Lymphatic Drainage Breast Massage in Breast Cancer Patients After Breast Conserving Surgery NCT06297265NA1 site📍 Los Angeles University of Southern California · Tests: Lymphedema Management, Questionnaire Administration, Adjuvant breast radiation therapy Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer NCT06631092Phase 1, Phase 22 sites📍 Erlangen📍 Heidelberg NEC Bio B.V · Tests: Oral DNA Vaccine Facility-Based Multi-Modal Rehab vs. Home-Based Resistance Exercise for Quality of Life in Breast Cancer Survivors NCT07465393NA1 site📍 New Taipei City Valeria Chiu · Tests: Multimodal Resistance and Relaxation Training, Home-Based Resistance Exercise Training Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients NCT06722599n/a1 site📍 Beijing Shu Wang Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT07288359Phase 1, Phase 216 sites📍 Atlanta📍 Nashville📍 San Antonio Novartis Pharmaceuticals · Tests: GVV858, Fulvestrant, Letrozole Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer NCT06123988NA3 sites📍 Phoenix📍 Miami📍 Boston University of Miami · Tests: Prolonged Overnight Fasting, Moderate-Intensity Exercise, General Health Education Sessions mHealth to Improve Medication Adherence Among Latina Breast Cancer Patients Experiencing Non-Medical Drivers of Health NCT07706127NA1 site📍 San Antonio The University of Texas Health Science Center at San Antonio · Tests: HT Helper app use plus patient navigation support, Patient Navigation support alone, Usual Care Real-world Bicohort Observational Study of a Pertuzumab Biosimilar in the Treatment of Breast Cancer: in the Neoadjuvant Setting and in First-line Metastatic Disease NCT07542496n/a2 sites📍 Algiers📍 Algiers Société Algérienne de Formation et Recherche en Oncologie A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors NCT07250386Phase 11 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: CEA-targeted CAR-T (Intravenous), CEA-targeted CAR-T (Intrapleural) A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors NCT05932862Phase 116 sites📍 Fountain Valley📍 Jacksonville📍 Orlando Exelixis · Tests: XL309, Olaparib DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients NCT06388122n/a1 site📍 Jacksonville Mayo Clinic · Tests: Biospecimen Collection PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients NCT05440227Phase 21 site📍 Taipei PhytoHealth Corporation · Tests: PG2 Lyo. Injection 500mg, Placebo 0.9% normal saline Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters. NCT07243002n/a1 site📍 London Novartis Pharmaceuticals Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors NCT05372640Phase 17 sites📍 Los Angeles📍 Los Angeles📍 Los Angeles National Cancer Institute (NCI) · Tests: Abemaciclib, BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing Phase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast Cancer NCT07817082Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: SHR- A1811 Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer NCT07695259Phase 41 site📍 Hangzhou Wen-Ming Cao · Tests: olaparib combined with trastuzumab and pertuzumab Omission of Local Therapies in Women Patients With HER2-positive or Triple-negative Breast Cancer NCT06938724Phase 21 site📍 Milan Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Tests: Omission of local therapies
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy